Inventera Inc.
KOSDAQ-listed biotech developing an iron-based nano-MRI contrast agent on its polysaccharide nanostructure drug delivery platform, Invinity™.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2018 and listed on KOSDAQ in 2026, Inventera is a biotech specializing in nanomedicine. It has developed its own polysaccharide-based nanostructure drug delivery platform, Invinity™, which controls surface charge and particle size to suppress protein corona formation and enable stable in-vivo dispersion and targeted delivery. Based on this platform, it is developing an iron (Fe)-based, disease-specific nano-MRI contrast agent intended to address the safety concerns of existing gadolinium (Gd)-based contrast agents.
Clinical trials
data.go.kr4 MFDS clinical trial authorisations · 2021–2025 (Phase 1/2a 2 · Phase 3 1 · Phase 2b 1)
- Phase 3NEMO-103주2025-06-17
9 trial sites
- Phase 1/2aINV-001주2023-11-15
2 trial sites
- Phase 2bNEMO-103주2023-03-29
3 trial sites
- Phase 1/2aNEMO-103주2021-04-02
1 trial site
R&D and key agreements
Source: DART corporate disclosureInvinity™ · 플랫폼 기술 · Polysaccharide-based nanostructure drug delivery platform; controls surface charge and particle size to suppress protein corona formation and enable targeted delivery
철(Fe) 기반 나노-MRI 조영제 · Disease-specific contrast agent candidate addressing safety concerns of gadolinium-based agents
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition